Zhang 2013.

Methods	Randomised clinical trial, China
Participants	100 hospitalised adults with viral hepatitis, and alcoholic liver disease, at nutritional risk according to the trialist. Male:Female = 80:20 Mean age = 49 years Exclusion criteria: Upper gastro‐intestinal haemorrhage within 2 weeks before admission, uncontrolled diabetes, malignant tumour, clinical manifestations of hepatic encephalopathy, clear infection, antiviral indications of hepatitis B cirrhosis in the prevention and treatment guidelines of chronic hepatitis (2010 version), but did not want to or could not receive nucleoside analogue antiviral treatment
Interventions	Experimental group: Enteral nutrition: Weekly recipes were prepared with 35 ˜ 40 kcal/(kg/day) , 1.2 ˜ 1.5 g/(kg/day) protein, 0.8 ˜ 1.2 g/(kg/day) amino acid and 350 ˜ 500 g/day carbohydrate. Additionally supplemented vitamins A, D, e, K, B and Se, were included on the 4th day in the daily meals. They were given yoghurt (or hot milk) of 100 ml and 15 g Noveliver compound protein granule (purchased from the Global Partner of Institute for Liver Cell Media, Myer Otec Co. California USA, which contained 18 kinds of amino acids including all essential amino acids, and folic acid, selenium, etc.) at bedtime. Nutrition intervention lasted for 4 weeks.(n = 50) Control group: Conventional diet(n = 50) Co‐interventions: Protecting liver therapy and antiviral therapy
Outcomes	Triceps skin fold, BMI, mid‐arm circumference, mid‐arm muscle circumference, self‐conscious symptoms, growth and decline of ascites, Albumin, pre‐albumin, cholinesterase, transaminase and bilirubin, blood coagulation index, HBV DNA and complications
Study dates	Not stated
Notes	We contacted the author by phone and received information on mortality, follow‐up length, and funding.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The author told us that he could not remember the specific method of randomisation.
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Participants and personnel were not blinded.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	The number of participants with incomplete data was not reported.
Selective reporting (reporting bias)	Unclear risk	No protocol could be obtained and the trial did not report on all‐cause mortality or serious adverse events.
For‐profit bias	Low risk	The trial was funded by Major special projects of science and technology bureau of Changchun (10SF05).
Other bias	Low risk	The trial appeared to be free of other components that could put it at risk of bias.